
## GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2023



S

## SENATE BILL DRS55071-NBa-173A

	Short Title: F	Right To	Try Individualized Treatments.	(Public)		
	Sponsors: S	Senator	Sawrey (Primary Sponsor).			
	Referred to:					
1			A BILL TO BE ENTITLED			
2	ΔΝ ΔΩΤ ΤΟ Ρ					
3	AN ACT TO PROVIDE ELIGIBLE PATIENTS THE RIGHT TO TRY INDIVIDUALIZED INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS, AND DEVICES TO TREAT					
4	LIFE-THREATENING OR SEVERELY DEBILITATING ILLNESSES AND TO					
5	APPROPRIATE FUNDS TO THE DEPARTMENT OF HEALTH AND HUMAN					
5	SERVICES					
7			of North Carolina enacts:			
3	SECTION 1. Article 23A of Chapter 90 of the General Statutes is amended by					
)	adding a new Pa		1	j		
)	0		"Part 3. Individualized Treatments.			
l	" <u>§ 90-325.30.</u> I	Definiti				
2			itions apply in this Part, unless the context requires oth	nerwise:		
3	<u>(1)</u>		ble facility. – Any institution operating under Federalw			
ŀ		the H	Protection of Human Subjects in accordance with 45 C	C.F.R. § 46 and 42		
		U.S.	<u>C. § 289(a).</u>			
)	<u>(2)</u>	<u>Elig</u> i	ble patient An individual who meets all of the follow	ving criteria:		
		<u>a.</u>	Has a life-threatening or severely debilitating illnes	ss, attested to by a		
			treating physician.			
		<u>b.</u>	Has, in consultation with a treating physician, con			
)			treatment options currently approved by the United	d States Food and		
_			Drug Administration.			
2		<u>c.</u>	Has received a recommendation from the treating pl			
			an individualized investigational drug, biological g			
•			for treatment of the life-threatening or severely debi			
		<u>d.</u>	Has given informed consent in writing to use of the			
5			investigational drug, biological product, or device for			
			life-threatening or severely debilitating illness or, if			
5			minor or is otherwise incapable of providing infor	· · · · · · · · · · · · · · · · · · ·		
)			parent or legal guardian has given informed consen			
)			of the individualized investigational drug, biolo	gical product, or		
		_	device.	· · · · · · · · · · · · · · · · · · ·		
		<u>e.</u>	Has documentation from the treating physician the			
			meets all of the criteria for this definition. This do			
			include an attestation from the treating physician physician was consulted in the creation of the	-		
5			consent required under this Part.	withen, informed		
			consent required under units rait.			



G	eneral Assemb	oly Of I	North Carolina	Session 2023
1	(3)	Indiv	idualized investigational drug, biological product	. or device. – A drug.
2		-	gical product, or device that is unique and produc	
3			n individual patient, based on their own gene	•
4			idualized gene therapy antisense oligonucleotid	
5			itigen vaccines.	
6	<u>(4)</u>		ution. – As defined in 45 C.F.R. § 46.102(f).	
7	$\overline{(5)}$		hreatening or severely debilitating illness. – As the	nose terms are defined
8	<u></u>		C.F.R. § 312.81.	
9	<u>(6)</u>	_	en, informed consent. – A written document that i	s signed by an eligible
0	<u></u>		nt; or if the patient is a minor, by a parent or leg	
1		_	it is incapacitated, by a designated health care age	
2		1	bower of attorney, that at a minimum includes all of	±
3		<u>a.</u>	An explanation of the currently approved produ	-
4		<u>u.</u>	the eligible patient's life-threatening or severely	
5		<u>b.</u>	An attestation that the eligible patient conc	-
.6		<u>U.</u>	physician in believing that all currently app	
.7			unlikely to prolong the eligible patient's life.	roved treatments are
.8		<u>c.</u>	Clear identification of the specific individualize	d investigational drug
9		<u>c.</u>	biological product, or device proposed for trea	
20			patient's terminal illness.	authent of the englote
21		<u>d.</u>	A description of the potentially best and wor	st outcomes resulting
22		<u>u.</u>	from use of the individualized investigational dr	
23			or device to treat the eligible patient's life-th	• • •
24			debilitating illness, along with a realistic descrip	
25			outcome. The description shall be based on the	
26			knowledge of the proposed treatment in	
27			awareness of the eligible patient's life-three	
28			debilitating illness and shall include a statemen	
29			new, unanticipated, different, or worse sympto	
30			and that death could be hastened by, the propose	-
31		<u>e.</u>	A statement that eligibility for hospice care ma	
32		<u>c.</u>	eligible patient begins treatment of the life-th	-
3			debilitating illness with an individualized	
5 4			biological product, or device and that hospice c	
5			if such treatment ends and the eligible patient me	
6				eets nospice engionity
0 7		<u>f.</u>	requirements.	ofit plan or third party
8		<u>1.</u>	A statement that the eligible patient's health ben administrator and provider are not obligated to	
19				
9 10			treatments consequent to the use of the individu	-
+0 41			drug, biological product, or device, unless spec	incarry required to do
+1 42		~	so by law or contract.	that he are the is light
+2 13		<u>g.</u>	A statement that the eligible patient understands	
			for all expenses consequent to the use of	
14 15			investigational drug, biological product, or	
+5 +6			liability extends to the eligible patient's esta	
			between the patient and the manufacturer of	ule drug, biological
7		Ŀ	product, or device states otherwise.	isible potient relation
18		<u>h.</u>	A statement that the eligible patient or, for an el	• •
19 50			minor or lacks capacity to provide informed con	
50			legal guardian consents to the use of the individu	ualized investigational

General Assembly Of North Carolina	Session 2023
drug, biological product, or device for treatm	nent of the life-threatening
or severely debilitating illness.	
"§ 90-325.31. Authorized access to and use of individualized	<u>l investigational drugs,</u>
biological products, or devices.	
(a) A manufacturer operating within an eligible facility and	d in accordance with all
applicable federal law may make available to an eligible patient, and	d an eligible patient may
request, the manufacturer's individualized investigational drug, biological drug, biologica	ogical product, or device
from an eligible facility or manufacturer operating within an eligible f	acility. However, nothing
in this Part shall be construed to require a manufacturer of an individual	lized investigational drug,
biological product, or device to make such individualized investig	gational drug, biological
product, or device available to an eligible patient.	
(b) <u>A manufacturer of an individualized investigational dru</u>	g, biological product, or
device may provide the individualized investigational drug, biologica	1 product, or device to an
eligible patient without receiving compensation or may require the e	eligible patient to pay the
costs of, or the costs associated with, the manufacture of the individual	lized investigational drug,
biological product, or device.	
"§ 90-325.32. No liability to heirs for outstanding debt related	to use of individualized
investigational drugs, biological products, or devices.	
If an eligible patient dies while being treated with an individual	ized investigational drug,
biological product, or device, the eligible patient's heirs are not liable	for any outstanding debt
related to the treatment, including any costs attributed to lack of in	surance coverage for the
treatment.	
<u>\$ 90-325.33.</u> Sanctions against health care providers prohibited.	
(a) <u>A licensing board shall not revoke, fail to renew, sus</u>	pend, or take any other
disciplinary action against a health care provider licensed under this Ch	napter, based solely on the
nealth care provider's recommendations to an eligible patient regardi	ng access to or treatment
with an individualized investigational drug, biological product, or devi	ice.
(b) An entity responsible for Medicare certification shall not ta	ake action against a health
care provider's Medicare certification based solely on the health care provider of the	rovider's recommendation
that a patient have access to an individualized investigational drug, biol	logical product, or device.
"§ 90-325.34. Prohibited conduct by State officials.	
No official, employee, or agent of this State shall block or atte	empt to block an eligible
patient's access to an individualized investigational drug, biolog	ical product, or device.
Counseling, advice, or a recommendation consistent with medical	standards of care from a
licensed health care provider does not constitute a violation of this sec	tion.
"§ 90-325.35. No private right of action against manufactu	urers of individualized
investigational drugs, biological products, or devices.	
No private right of action may be brought against a manufactu	urer of an individualized
investigational drug, biological product, or device, or against any other	person or entity involved
in the care of an eligible patient using an individualized investigational	l drug, biological product,
or device, for any harm caused to the eligible patient resulting from	use of the individualized
investigational drug, biological product, or device as long as the manuf	facturer or other person or
entity has made a good-faith effort to comply with the provisions of the	-
reasonable care in actions undertaken pursuant to this Part.	
"§ 90-325.36. Insurance coverage of clinical trials.	
Nothing in this Part shall be construed to affect a health benefit pl	an's obligation to provide
coverage for an insured's participation in a clinical trial pursuant to G.	
<b>SECTION 2.</b> There is appropriated from the General Fu	
Health and Human Services the nonrecurring sum of fifty thousand	-

50 2024-2025 fiscal year to implement the provisions of this act.

## **General Assembly Of North Carolina**

SECTION 3. Section 1 of this act becomes effective October 1, 2024. Section 2 of 1 this act becomes effective July 1, 2024. The remainder of this act is effective when it becomes

2 3 law.